Literature DB >> 9537323

Altered nociception, analgesia and aggression in mice lacking the receptor for substance P.

C De Felipe1, J F Herrero, J A O'Brien, J A Palmer, C A Doyle, A J Smith, J M Laird, C Belmonte, F Cervero, S P Hunt.   

Abstract

The peptide neurotransmitter substance P modulates sensitivity to pain by activating the neurokinin-1 (NK-1) receptor, which is expressed by discrete populations of neurons throughout the central nervous system. Substance P is synthesized by small-diameter sensory 'pain' fibres, and release of the peptide into the dorsal horn of the spinal cord following intense peripheral stimulation promotes central hyperexcitability and increased sensitivity to pain. However, despite the availability of specific NK-1 antagonists, the function of substance P in the perception of pain remains unclear. Here we investigate the effect of disrupting the gene encoding the NK-1 receptor in mice. We found that the mutant mice were healthy and fertile, but the characteristic amplification ('wind up') and intensity coding of nociceptive reflexes was absent. Although substance P did not mediate the signalling of acute pain or hyperalgesia, it was essential for the full development of stress-induced analgesia and for an aggressive response to territorial challenge, demonstrating that the peptide plays an unexpected role in the adaptive response to stress.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9537323     DOI: 10.1038/32904

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  171 in total

Review 1.  Research on genes: promises and limitations.

Authors:  S N Young; R M Palmour
Journal:  J Psychiatry Neurosci       Date:  1999-09       Impact factor: 6.186

Review 2.  Visceral pain-central sensitisation.

Authors:  F Cervero
Journal:  Gut       Date:  2000-12       Impact factor: 23.059

Review 3.  Breathing: rhythmicity, plasticity, chemosensitivity.

Authors:  Jack L Feldman; Gordon S Mitchell; Eugene E Nattie
Journal:  Annu Rev Neurosci       Date:  2003-02-13       Impact factor: 12.449

4.  Immunocytochemical analyses and targeted gene disruption of GTPBP1.

Authors:  S Senju; K Iyama; H Kudo; S Aizawa; Y Nishimura
Journal:  Mol Cell Biol       Date:  2000-09       Impact factor: 4.272

5.  Detection of the full-length transcript variant for neurokinin-1 receptor in human whole blood associated with enhanced reinforcement of clot by substance-P.

Authors:  Toshiharu Azma; Yuki Sugimoto; Hiroyuki Kinoshita; Taishin Ito; Masanori Tsukamoto; Hiroshi Hoshijima; Masakazu Nakao; Hirosato Kikuchi
Journal:  J Thromb Thrombolysis       Date:  2012-05       Impact factor: 2.300

6.  Opioid signaling in mast cells regulates injury responses associated with heterotopic ossification.

Authors:  Lixin Kan; Amelia A Mutso; Tammy L McGuire; Apkar Vania Apkarian; John A Kessler
Journal:  Inflamm Res       Date:  2013-12-11       Impact factor: 4.575

7.  Preprotachykinin-A gene disruption attenuates nociceptive sensitivity after opioid administration and incision by peripheral and spinal mechanisms in mice.

Authors:  Peyman Sahbaie; Xiaoyou Shi; Xiangqi Li; Deyong Liang; Tian-Zhi Guo; Yanli Qiao; David C Yeomans; Wade S Kingery; J David Clark
Journal:  J Pain       Date:  2012-10       Impact factor: 5.820

8.  Neurokinin B induces oedema formation in mouse lung via tachykinin receptor-independent mechanisms.

Authors:  Andrew D Grant; Roksana Akhtar; Norma P Gerard; Susan D Brain
Journal:  J Physiol       Date:  2002-09-15       Impact factor: 5.182

9.  Contribution of neurokinin 1 receptors in the cutaneous orofacial inflammatory pain.

Authors:  Philippe Luccarini; Mélaine Henry; Pedro Alvarez; Anne-Marie Gaydier; Radhouane Dallel
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-09-27       Impact factor: 3.000

Review 10.  The recent progress in research on effects of anesthetics and analgesics on G protein-coupled receptors.

Authors:  Kouichiro Minami; Yasuhito Uezono
Journal:  J Anesth       Date:  2012-10-26       Impact factor: 2.078

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.